RNA technology takes on diabetes: first human trial of exenatide nanoparticle injection
NCT ID NCT07347080
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a single dose of a new type of exenatide injection (CR059) in 9 Chinese adults with type 2 diabetes. The exenatide is delivered using circular RNA wrapped in lipid nanoparticles, a technology similar to some vaccines. The main goal is to check safety and tolerability, while also looking at how the drug moves through the body and affects blood sugar. Because it's a very small, first-in-human study, it's mainly about gathering initial safety data.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
exenatide circular RNA-lipid nanoparticle injection (CR059)
What this could lead to
If it works, this could lead to a new way to deliver exenatide for better blood sugar control in type 2 diabetes.
What could go wrong
This is a very early, small trial with only 9 people, so it may not show clear benefits or could have unexpected side effects. Success is far from guaranteed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGLuoyang, Henan, 310015, China
Contact Phone: •••-•••-•••• Email: •••••@•••••